Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02682-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Rikako Ito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Ascites, Cytokines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asahi Kasei Medical Corporation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail. Thus, we comprehensively analyzed cytokines in ascites fluid (AF) and serum before and after CART to determine the influence of cytokines on the safety and efficacy of CART.
Methods
Thirteen ovarian cancer patients with refractory malignant ascites who underwent CART were enrolled. We comprehensively analyzed 27 cytokines in AF and serum before and after CART. Simultaneously, vital measurements, blood tests, adverse event recordings, and QOL assessments were performed to examine the relationships between the cytokines in AF and serum.
Results
Interleukin (IL)-5, IL-6, IL-10, and monocyte chemoattractant protein-1 levels were increased in the concentrated AF and in the serum immediately after reinfusion, but they decreased after 24 h. Body temperature also increased immediately after reinfusion, and decreased after 24 h. The CRP level at 24 h after reinfusion was increased, and was positively correlated with the IL-6 level. A QOL assessment using the Cancer Fatigue Scale revealed significantly lower scores after CART.
Conclusions
The results indicate that the cytokine-induced fever and increased inflammatory response after CART were temporary, and that CART is safe. Additionally, QOL improved after CART. Thus, CART appears safe and effective for treating patients with refractory cancerous ascites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. mkagabu@iwate-med.ac.jp.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, 3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan.
Förderung
- Asahi Kasei Medical Corporation
Zitieren
APA
Ito, R., Kagabu, M., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Shoji, T., Hirayama, T., Terao, Y., & Baba, T. (2025). Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02682-1
Vancouver
Ito R, Kagabu M, Sato S, Takatori E, Kaido Y, Nagasawa T, et al. Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02682-1
BibTeX
@article{Ito2025,
author = {Ito, Rikako and Kagabu, Masahiro and Sato, Sho and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Shoji, Tadahiro and Hirayama, Takashi and Terao, Yasuhisa and Baba, Tsukasa},
title = {Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02682-1}
}
EUVIMED